Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)
(Stock Code: 01099)
ANNOUNCEMENT
PRINCIPAL FINANCIAL DATA OF CNMDC
FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2019
This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).
Reference is made to the overseas regulatory announcement dated 25 October 2019 (the "Announcement") issued by Sinopharm Group Co. Ltd. (the "Company") in relation to the unaudited consolidated balance sheet, income statement and cash flow statement, and the unaudited balance sheet, income statement and cash flow statement of China National Medical Device Co., Ltd. ("CNMDC"), a subsidiary of the Company for the nine months ended 30 September 2019 issued on the websites of China Money and Shanghai Clearing House by CNMDC.
The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data of CNMDC for the nine months ended 30 September 2019 as set out in this Announcement.
PRINCIPAL FINANCIAL DATA OF THE CONSOLIDATED FINANCIAL STATEMENTS
Unit: Yuan
Currency: RMB
Changes of this period
Current period Same period of last year over same period of last year
Revenue
Operating profit
Total comprehensive income attributable to owners of the parent company
Net cash flow arising from operating activities
Total assets
Total equity attributable to owners (or shareholders) of the parent company
29,934,619,653.22
1,098,583,509.73
471,956,024.99
-2,175,883,126.95
At the end of the reporting period
29,761,951,380.95
4,480,712,841.99
21,904,786,847.71 36.66%
788,574,346.26 39.31%
349,996,672.13 34.85%
-2,367,835,691.78-8.11%
Changes of At the beginning of the this period-
reporting period end over the beginning of
this period
21,868,609,223.01 36.09%
4,106,634,043.32 9.11%
By order of the Board of
Sinopharm Group Co. Ltd.
Li Zhiming
Chairman
Shanghai, the PRC
25 October 2019
As at the date of this announcement, the executive directors of the Company are Mr. Li Zhiming, Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Ma Ping, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wen Deyong, Ms. Guan Xiaohui and Ms. Dai Kun; and the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Tan Wee Seng, Mr. Liu Zhengdong, Mr. Zhuo Fumin and Mr. Chen Fangruo.
-
The Company is registered as a non-Hong Kong company under the Hong Kong
Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd.".
Attachments
- Original document
- Permalink
Disclaimer
Sinopharm Group Co. Ltd. published this content on 25 October 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 October 2019 15:50:17 UTC